Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Abstract Background Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal cancer (mCRC). This multicenter, single-arm, phase II, exploratory stu...

Full description

Bibliographic Details
Main Authors: Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai, Zhekang Jin, Liuhong Wang, Ying Yuan, Kefeng Ding
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Medicine
Subjects:
Metastatic colorectal cancer
Anlotinib
Capecitabine
Oxaliplatin
First-line therapy
Online Access:https://doi.org/10.1186/s12916-022-02357-6

Internet

https://doi.org/10.1186/s12916-022-02357-6

Similar Items